Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04552886 | Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult Glioblastoma | PHASE1 | COMPLETED | 17 | — | — | Oct 1, 2021 | Nov 1, 2023 | Jan 10, 2024 | - | — |
| Name | Type | Description |
|---|---|---|
| TH-1 Dendritic Cell Immunotherapy | BIOLOGICAL | Adult patients with histopathologically diagnosed glioblastoma will be eligible for this novel, personalized dendritic cell vaccine after completing standard of care chemoradiation. |